Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

Shorts are becoming more impotent as news gets out to the market about the huge potential that the company's patented MANF technology offers.

This is substantially undervalued. It should be trading in the .15-.20 range currently.

If you're wondering what stock may be the "2013 Stock of the Year" and what C.E.O. may be the "2013 Bio-Tech C.E.O. of the Year" I think you've already got a head start on knowing the winners.

Exciting months ahead for the shareholders.